Literature DB >> 32346110

Redeployment: a new paradigm for ophthalmology professionals.

Michelle S Attzs1, Bansri K Lakhani2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32346110      PMCID: PMC7187662          DOI: 10.1038/s41433-020-0915-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   4.456


× No keyword cloud information.

To the Editor:

As the world is plunged into new and uncertain times, ‘redeployment’ is emerging as the novel word in the lexicon of ophthalmologists. At the end of 2019, the World Health Organization was notified by health officials in the Chinese province of Hubei, about the presentation of pneumonia of unknown aetiology. Subsequent biological and genomic testing revealed a new type of coronavirus, which we now know as COVID-19 [1]. Following the discovery of the first case, there has been an exponential rise in those infected, and as of 3 April 2020, there have been 1,088,878 confirmed cases of COVID-19, with a total of 58,382 deaths [2]. In our response to this pandemic, Ophthalmology in the United Kingdom (U.K.) has seen a dramatic change in its operations. The Royal College of Ophthalmologists (RCOphth) has produced guidance on how ophthalmic services in the U.K. should endure the current crisis [3], in line with a directive from NHS England and NHS Improvement to postpone all non-urgent outpatient and surgical workload [4]. The RCOphth website offers guidance on the risk stratification of patients to ensure that none suffer permanent sight loss as a result of the delay to their appointment or treatment, whilst protecting both staff and patients by reducing the departmental footfall [5]. The dramatic decrease in clinical and surgical activity in Ophthalmology departments across the U.K. has resulted in the redeployment of Ophthalmology doctors to alternative, frontline hospital environments to assist with the COVID-19 response. Redeployment may be a known concept within the NHS, but it is certainly new to the vocabulary of the Ophthalmology departments. Never, in its 70-year history, has the NHS encountered the need to implement such widespread, safe restructuring of its workforce [6]. The local unit of the authors of this article has begun a staged process, with the most junior trainees being redeployed to acute wards as part of a mega SHO rota between ENT, Maxillofacial and Neurosurgery. In preparation for what seems like the inevitable, senior registrars and consultants have started a process of staged shadowing and simulation training, in order to prepare for the time when they are required in these different hospital environments. Whilst this is occurring, the ophthalmic service is operating at around 20% with emergency eye care provision still paramount. The redeployment of Ophthalmology doctors gives rise to many questions. As doctors, what level of basic medical knowledge and skills should we retain throughout our training? Should all levels of Ophthalmology doctors be redeployed? How will we cope with the unfamiliar working patterns, unknown teams and new bosses, especially given the current climate of crisis? The key messages from the General Medical Council [7], the four Statutory Education Bodies [8] and Academy of Medical Royal Colleges [9] are consistent; advice must always be sought when working in an unfamiliar environment, work within your competence, and most importantly, remember no one is alone in this new journey of redeployment and that everyone has the same anxieties and concerns [10].
  1 in total

1.  How can I cope with redeployment?

Authors:  Abi Rimmer
Journal:  BMJ       Date:  2020-03-30
  1 in total
  2 in total

1.  A prospective evaluation of the clinical safety and effectiveness of a COVID-19 Urgent Eyecare Service across five areas in England.

Authors:  Alexander G Swystun; Christopher J Davey
Journal:  Ophthalmic Physiol Opt       Date:  2021-11-10       Impact factor: 3.117

2.  Impact of COVID-19 pandemic and lockdown on eye emergencies.

Authors:  Alicia Poyser; Sundeep S Deol; Lina Osman; Helen J Kuht; Tharsica Sivagnanasithiyar; Roslyn Manrique; Linda O Okafor; Ian DeSilva; David Sharpe; Vijay Savant; Usman Sarodia; Nagini Sarvananthan; Ray Chaudhuri; Somnath Banerjee; Joyce Burns; Mervyn G Thomas
Journal:  Eur J Ophthalmol       Date:  2020-11-19       Impact factor: 2.597

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.